| Detected | Trial | Change |
|---|---|---|
| 2026-06-06 | NCT04074096 Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma… |
date change Primary completion pushed: 2026-03-27 -> 2026-05-07 |
| 2026-06-06 | NCT04074096 Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma… |
date change Completion pushed: 2026-03-27 -> 2027-03-27 |
| 2026-06-04 | NCT05308446 Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or… |
date change Primary completion moved earlier: 2026-09-30 -> 2026-02-28 |
| 2026-06-04 | NCT05308446 Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or… |
date change Completion pushed: 2026-09-30 -> 2027-06-01 |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT05615818 | Personalized Medicine for Advanced Biliary Cancer Patients | Biliary Tract Neoplasms | Recruiting |
| NCT04657991 | A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab)… | Melanoma | Active, Not Recruiting |
| NCT04607421 | A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With… | Neoplasms | Active, Not Recruiting |
| Phase 2/3 | |||
| NCT05710406 | Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for… | Colon Adenocarcinoma | Active, Not Recruiting |
| Phase 2 | |||
| NCT04324112 | Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL | Hairy Cell Leukemia | Recruiting |
| NCT05026983 | Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous… | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Recruiting |
| NCT06578559 | Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF… | Colorectal Cancer | Active, Not Recruiting |
| NCT05217446 | A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to… | Metastatic Colorectal Cancer | Active, Not Recruiting |
| NCT04061980 | Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With… | BRAF NP_004324.2:p.V600M | Active, Not Recruiting |
| NCT05195632 | Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E… | Non-Small Cell Lung Cancer | Active, Not Recruiting |
| NCT05308446 | Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or… | Metastatic Colon Adenocarcinoma | Active, Not Recruiting |
| NCT04074096 | Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma… | Malignant Melanoma | Active, Not Recruiting |
| NCT03839342 | Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E… | Solid Tumor | Active, Not Recruiting |
| NCT02910700 | Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating… | Metastatic Malignant Neoplasm in the Brain | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT04017650 | Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable… | BRAF NP_004324.2:p.V600E | Active, Not Recruiting |
| Phase 1 | |||
| NCT04903119 | Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma | Metastatic Melanoma | Recruiting |
| NCT05985954 | Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With… | Metastatic Colorectal Cancer | Recruiting |
| Early Phase 1 | |||
| NCT03543969 | Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma | Melanoma (Skin) | Active, Not Recruiting |
| NCT07318389 | ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic… | Dynamic Tumor Resistance | Not Yet Recruiting |